GoodRx (NASDAQ:GDRX) Issues Earnings Results

Key Points

• Quarterly results: GoodRx reported $0.07 EPS, meeting consensus, and revenue of $194.01M which beat estimates but was down 4.4% year-over-year.
• Market valuation: Shares traded at $2.57 with a market cap of $880.4M and a P/E of 28.56, trading near the lower end of its 12‑month $1.77–$5.81 range.
• Analyst and ownership backdrop: The consensus rating is "Hold" with an average price target of $3.85, and institutional investors own 63.77% of the stock after several large funds increased positions.

GoodRx (NASDAQ:GDRX - Get Free Report) announced its earnings results on Wednesday. The company reported $0.07 EPS for the quarter, meeting analysts' consensus estimates of $0.07, FiscalAI reports. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. The business had revenue of $194.01 million during the quarter, compared to analysts' expectations of $185.12 million. During the same period in the prior year, the company earned $0.09 earnings per share. The firm's revenue was down 4.4% on a year-over-year basis.

GoodRx Price Performance

Shares of GDRX traded up $0.01 during mid-day trading on Wednesday, reaching $2.57. The stock had a trading volume of 2,005,226 shares, compared to its average volume of 1,447,083. The firm has a market cap of $880.40 million, a price-to-earnings ratio of 28.56, a PEG ratio of 1.77 and a beta of 1.54. GoodRx has a 12 month low of $1.77 and a 12 month high of $5.81. The business has a fifty day moving average of $2.20 and a 200 day moving average of $2.59. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.61 and a current ratio of 2.61.

Hedge Funds Weigh In On GoodRx

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of GoodRx by 7.3% in the third quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company's stock worth $38,947,000 after purchasing an additional 624,182 shares during the period. Ameriprise Financial Inc. boosted its position in shares of GoodRx by 4.0% in the second quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company's stock worth $24,001,000 after purchasing an additional 184,734 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of GoodRx by 6.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,650,452 shares of the company's stock worth $7,183,000 after acquiring an additional 152,934 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of GoodRx by 188.0% during the fourth quarter. AQR Capital Management LLC now owns 1,158,546 shares of the company's stock worth $3,140,000 after acquiring an additional 756,209 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of GoodRx by 22.1% during the fourth quarter. Geode Capital Management LLC now owns 1,135,563 shares of the company's stock worth $3,078,000 after acquiring an additional 205,628 shares during the last quarter. 63.77% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Leerink Partners reaffirmed an "outperform" rating and set a $3.00 target price on shares of GoodRx in a report on Thursday, February 26th. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of GoodRx in a report on Friday, February 27th. Wall Street Zen cut shares of GoodRx from a "buy" rating to a "hold" rating in a report on Sunday, January 25th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of GoodRx in a report on Friday, April 10th. Finally, Mizuho reduced their target price on shares of GoodRx from $4.00 to $3.00 and set a "neutral" rating for the company in a report on Friday, February 27th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, GoodRx has an average rating of "Hold" and an average price target of $3.85.

GoodRx Company Profile

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.